PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Hyoscine Butylbromide→

Hyoscine Butylbromide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
149-64-4
Molecular formula
C21H30BrNO4
Molecular weight
440.37 g/mol
Drug class
Peripheral antimuscarinic antispasmodicquaternary ammonium hyoscine derivative
Mechanism of action
Blocks muscarinic acetylcholine receptors in gastrointestinal, biliary and genitourinary smooth muscle and also has ganglion-blocking activity within the visceral wall. Its quaternary ammonium structure limits entry into the central nervous system.
Indications / reported uses
  • Relief of gastrointestinal and genitourinary smooth-muscle spasm
  • Symptomatic relief of irritable bowel syndrome
  • Injection products are used for acute spasm such as renal or biliary colic and during selected diagnostic procedures; indication depends on formulation

Sources: UK SmPC — Hyoscine butylbromide 10 mg · UK SmPC — Hyoscine butylbromide 20 mg · UK SmPC — Hyoscine butylbromide injection · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Hyoscine Butylbromide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Hyoscine Butylbromide Permitted Daily Exposure (PDE) report (the Hyoscine Butylbromide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Hyoscine Butylbromide Occupational Exposure Limit (OEL) report (the Hyoscine Butylbromide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.